EP1594433A4 - Cancer therapy sensitizer - Google Patents

Cancer therapy sensitizer

Info

Publication number
EP1594433A4
EP1594433A4 EP04702173A EP04702173A EP1594433A4 EP 1594433 A4 EP1594433 A4 EP 1594433A4 EP 04702173 A EP04702173 A EP 04702173A EP 04702173 A EP04702173 A EP 04702173A EP 1594433 A4 EP1594433 A4 EP 1594433A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
therapy sensitizer
sensitizer
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04702173A
Other languages
German (de)
French (fr)
Other versions
EP1594433B8 (en
EP1594433B1 (en
EP1594433A3 (en
EP1594433A2 (en
Inventor
Isabelle T Tai
Lan Bo Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to EP12183770.2A priority Critical patent/EP2561887B8/en
Publication of EP1594433A3 publication Critical patent/EP1594433A3/en
Publication of EP1594433A2 publication Critical patent/EP1594433A2/en
Publication of EP1594433A4 publication Critical patent/EP1594433A4/en
Application granted granted Critical
Publication of EP1594433B1 publication Critical patent/EP1594433B1/en
Publication of EP1594433B8 publication Critical patent/EP1594433B8/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP04702173.8A 2003-01-14 2004-01-14 Cancer therapy sensitizer Expired - Lifetime EP1594433B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12183770.2A EP2561887B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44000903P 2003-01-14 2003-01-14
US440009P 2003-01-14
PCT/US2004/000901 WO2004064785A2 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12183770.2A Division-Into EP2561887B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer
EP12183770.2A Division EP2561887B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Publications (5)

Publication Number Publication Date
EP1594433A3 EP1594433A3 (en) 2005-10-20
EP1594433A2 EP1594433A2 (en) 2005-11-16
EP1594433A4 true EP1594433A4 (en) 2008-10-01
EP1594433B1 EP1594433B1 (en) 2016-01-13
EP1594433B8 EP1594433B8 (en) 2016-12-21

Family

ID=32771768

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12183770.2A Expired - Lifetime EP2561887B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer
EP04702173.8A Expired - Lifetime EP1594433B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12183770.2A Expired - Lifetime EP2561887B8 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Country Status (7)

Country Link
US (2) US7638272B2 (en)
EP (2) EP2561887B8 (en)
JP (3) JP5568208B2 (en)
CA (2) CA2513251C (en)
ES (2) ES2565327T3 (en)
HK (1) HK1082378A1 (en)
WO (1) WO2004064785A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
ATE527370T1 (en) 2004-11-30 2011-10-15 Univ British Columbia SPARC PROMOTOR MUTATIONS RELATED TO DRUG RESISTANCE AND RELATED PROCEDURES
EP1869077A2 (en) 2005-02-18 2007-12-26 Abraxis BioScience, Inc. Q3 sparc deletion mutant and uses thereof
ES2406929T3 (en) * 2006-06-26 2013-06-10 The University Of British Columbia Cysteine-rich and secreted acidic protein (SPARC) as chemotherapeutic sensitizers
EP2069794A1 (en) * 2006-10-03 2009-06-17 University of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
CN101678078B (en) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 SPARC and methods of use thereof
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
JP5496220B2 (en) * 2008-12-05 2014-05-21 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Albumin-binding peptide-mediated disease targeting
AU2010253747B2 (en) 2009-05-28 2013-07-11 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to chemotherapy
GB201018664D0 (en) * 2010-11-05 2010-12-22 Msd Biolog Uk Ltd Expression process
JP2018533578A (en) * 2015-10-30 2018-11-15 モナシュ ユニバーシティー Methods and compositions for improving glucose metabolism
KR101804246B1 (en) 2015-11-18 2017-12-04 주식회사 메타신 Pharmaceutical composition containing a FSTL1 protein for the prevention and treatment of osseous metabolic diseases
KR101804241B1 (en) 2015-11-20 2017-12-04 주식회사 메타신 Pharmaceutical composition containing a FSTL1 protein for the Suppression of cancer metastasis
KR101804248B1 (en) 2015-11-25 2017-12-04 주식회사 메타신 Pharmaceutical composition containing a FSTL1 protein for the prevention and treatment of cancer
EP3411058B1 (en) * 2016-02-02 2023-03-08 Splash Pharmaceuticals, Inc. Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
SE2000055A1 (en) * 2020-03-15 2021-09-16 Martin Ivanov Denev Use of photohydraulic mechanical shock, for selective bursting of relatively weaker cell membranes of cancer cells, which have weaker cell membranes than healthy cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
ATE110108T1 (en) 1987-12-11 1994-09-15 Whitehead Biomedical Inst GENETIC MODIFICATION OF ENDOTHELIAL CELLS.
ATE152169T1 (en) 1988-02-05 1997-05-15 Whitehead Biomedical Inst MODIFIED HEPATOCYTES AND THEIR APPLICATION
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DK0747485T3 (en) 1989-11-06 1999-08-16 Cell Genesys Inc Preparation of proteins using homologous recombination
EP0779362B2 (en) 1989-12-22 2012-06-13 Laboratoires Serono SA DNA constructs for endogenous gene activation and expression modification
EP0568537B1 (en) 1990-10-31 1998-02-04 Somatix Therapy Corporation Genetic modification of endothelial cells
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
JPH08506664A (en) * 1993-02-01 1996-07-16 セック，リミテッド Method and apparatus for DNA sequencing
US5738852A (en) 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
JPH09235223A (en) * 1995-12-26 1997-09-09 Nisshin Flour Milling Co Ltd Multidrug resistance-overcoming agent
AU5431098A (en) 1996-11-07 1998-05-29 Wistar Institute Of Anatomy And Biology, The Sparc-deficient transgenic mice
ATE348155T1 (en) 1996-11-20 2007-01-15 Introgen Therapeutics Inc AN IMPROVED METHOD FOR PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
AU5333298A (en) 1996-12-27 1998-07-31 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
ATE389712T1 (en) 1997-01-31 2008-04-15 Edward P Cohen CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENE CELLS
DE19740571C1 (en) 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Antigen-specific stimulation of T cells
US6475784B1 (en) * 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
DE69900746T2 (en) 1998-01-30 2002-08-14 Scios Inc CONTROLLED ADMINISTRATION OF PEPTIDES OR PROTEINS
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US6387664B1 (en) 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
CA2374141A1 (en) 1999-05-28 2000-12-07 University Of Virginia Patent Foundation Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
DE60043547D1 (en) 1999-09-24 2010-01-28 Mayo Foundation THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES OF THE RECOMBINANT FAMILY OF PARAMYXOVIRIDAE
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
MXPA02003384A (en) 1999-10-04 2002-08-20 Vion Pharmaceuticals Inc Compositions and methods for tumor-targeted delivery of effector molecules.
JP2003530893A (en) 2000-04-25 2003-10-21 ディーエヌエー サイエンシーズ インコーポレーテッド Detection of nucleotide sequence variation by proofreading activity of polymerase
AU2001268053A1 (en) 2000-07-05 2002-01-14 Eli Lilly And Company Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
WO2002064025A2 (en) * 2001-02-15 2002-08-22 Mount Sinai School Of Medicine Of New York University Inhibition of atf2 activity to treat cancer
WO2003072714A2 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US6814248B2 (en) * 2002-08-08 2004-11-09 Dtl Technology Limited Partnership Plastics container with recessed handgrip features and associated method and apparatus for manufacture thereof
JP2006512924A (en) 2002-08-15 2006-04-20 ジェンザイム・コーポレーション Brain endothelial cell expression pattern
US7485414B2 (en) * 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
EP1514929A1 (en) * 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
G.K. YIU ET AL: "SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells", AMERICAN JOURNAL OF PATHOLOGY, vol. 159, no. 2, February 2001 (2001-02-01), pages 609 - 622, XP002983766 *
I.A. CREE ET AL: "Chemosensitization of Solid Tumor Cells by Alteration of their Susceptibility to Apoptosis", CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 3, no. 4, April 2002 (2002-04-01), pages 641 - 647, XP008095641 *
N. DHANESUAN ET AL: "Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition.", BREAST CANCER RESEARCH, vol. 75, no. 1, September 2002 (2002-09-01), pages 73 - 85, XP002493062 *
See also references of WO2004064785A2 *
U. STEIN ET AL: "Reversal of Multidrug Resistance by Transduction of Cytokine Genes into Human Colon Carcinoma Cells", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, no. 19, 2 October 1996 (1996-10-02), pages 1383 - 1392, XP002493063 *

Also Published As

Publication number Publication date
CA2513251A1 (en) 2004-08-05
US7638272B2 (en) 2009-12-29
CA2802143C (en) 2018-06-19
EP1594433B8 (en) 2016-12-21
HK1082378A1 (en) 2006-06-09
EP2561887A3 (en) 2013-03-27
CA2513251C (en) 2013-03-19
EP2561887B8 (en) 2016-12-21
JP2012197294A (en) 2012-10-18
ES2565327T3 (en) 2016-04-04
US20060088511A1 (en) 2006-04-27
EP1594433B1 (en) 2016-01-13
ES2565496T3 (en) 2016-04-05
JP2006517926A (en) 2006-08-03
WO2004064785A9 (en) 2004-09-30
US8071294B2 (en) 2011-12-06
US20100151006A1 (en) 2010-06-17
JP2015057394A (en) 2015-03-26
JP5568208B2 (en) 2014-08-06
EP1594433A2 (en) 2005-11-16
WO2004064785A3 (en) 2005-10-20
CA2802143A1 (en) 2004-08-05
EP2561887A2 (en) 2013-02-27
EP2561887B1 (en) 2016-01-13
WO2004064785A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
HK1082378A1 (en) Cancer therapy sensitizer
EP1482970A4 (en) Cancer therapy
EP1535610A4 (en) Therapeutic agent for cancer
HK1102757A1 (en) Therapy of platinum-resistant cancer
EP1672978A4 (en) Cobalamin conjugates for anti-tumor therapy
EP1594433A3 (en) Cancer therapy sensitizer
EP1677805A4 (en) Pancreatic cancer treatment
GB0428187D0 (en) Cancer treatment
GB0327384D0 (en) Gene therapy
GB0326578D0 (en) Cancer diagnosis and therapy
GB0226595D0 (en) Cancer therapy determination
EP1595546A4 (en) Remedy for cancer
GB0404675D0 (en) Cancer treatment
GB0223325D0 (en) Treating cancer
GB0303289D0 (en) Combination therapy
PL1618130T3 (en) Therapeutic cancer vaccine
GB2383538B (en) Cancer treatment
GB0414885D0 (en) Cancer therapy
AU2003238722A8 (en) Cancer therapy by modulating cdc42-activity
GB0327499D0 (en) Cancer treatment
EP1646282A4 (en) Genetic vaccines for cancer therapy
GB0218725D0 (en) Cancer related methods
GB0213474D0 (en) Tumour therapy
GB0329081D0 (en) Radiotherapy apparatus
GB0329512D0 (en) Combination therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/00 19850101ALI20051125BHEP

Ipc: A61K 31/00 19850101ALI20051125BHEP

Ipc: A01N 61/00 19850101AFI20051125BHEP

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082378

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20080902

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/39 20060101AFI20080825BHEP

Ipc: A61K 45/06 20060101ALI20080825BHEP

Ipc: A61K 31/00 20060101ALI20080825BHEP

17Q First examination report despatched

Effective date: 20100910

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20150527BHEP

Ipc: A61K 31/00 20060101ALI20150527BHEP

Ipc: A61K 31/7048 20060101ALI20150527BHEP

Ipc: A61K 31/4745 20060101ALI20150527BHEP

Ipc: A61K 45/06 20060101ALI20150527BHEP

Ipc: A61P 35/00 20060101ALI20150527BHEP

Ipc: A61K 33/24 20060101ALI20150527BHEP

Ipc: A61K 38/39 20060101AFI20150527BHEP

Ipc: A61K 31/513 20060101ALI20150527BHEP

INTG Intention to grant announced

Effective date: 20150609

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150720

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004048501

Country of ref document: DE

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, US

Free format text: FORMER OWNER: DANA-FARBER CANCER INSTITUTE, BOSTON, MASS., US

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 770048

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160215

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004048501

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2565327

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160404

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 770048

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160414

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1082378

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160513

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004048501

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004048501

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004048501

Country of ref document: DE

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, US

Free format text: FORMER OWNER: DANA-FARBER CANCER INSTITUTE, BOSTON, MASS., US

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004048501

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, GB

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

26N No opposition filed

Effective date: 20161014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004048501

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20221201

Year of fee payment: 20

Ref country code: FR

Payment date: 20221208

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230213

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221213

Year of fee payment: 20

Ref country code: DE

Payment date: 20221130

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004048501

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240126

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240115